Securities Law Firm Files Lawsuit Against MoonLake Immunotherapeutics for Securities Fraud

Strategic Insights -

Leading securities law firm has filed a lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500.

MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases. During the relevant period, MoonLake conducted highly anticipated Phase 3 VELA trials for sonelokimab, an investigational therapeutic designed to treat adult participants with moderate to severe hidradenitis suppurativa. MoonLake told investors that its clinical data, including results from its Phase 2 MIRA trial, translate into higher clinical responses for patients, and provide ample opportunity for differentiation of sonelokimab versus all competitors. However, as alleged, the Company's clinical data and Nanobody structure did not confer a superior clinical benefit over its competitors, calling into question the drug's chances for regulatory approval and commercial viability.

The stock price of MoonLake fell $55.75 per share, or nearly 90%, following the release of disappointing Phase 3 trial results, which raised concerns about the drug's viability. Investors who purchased MoonLake stock during the class period may be eligible to participate in the lawsuit.

Key Takeaways:

  • The lawsuit alleges that MoonLake Immunotherapeutics and certain of its senior executives violated federal securities laws by making false or misleading statements about the Company's clinical trials for sonelokimab.
  • MoonLake told investors that their clinical data and Nanobody structure conferred a superior clinical benefit over competitors, but this was allegedly not the case.
  • The Company's stock price fell nearly 90% after the release of disappointing Phase 3 trial results.
  • Investors who purchased MoonLake stock during the class period may be eligible to participate in the lawsuit and seek compensation for their losses.
  • Bleichmar Fonti & Auld LLP, the law firm filing the lawsuit, has a reputation for successfully representing plaintiffs in securities class actions and shareholder litigation, recovering over $900 million in value for previous clients.

Statistics:

  • 90%: The decline in MoonLake's stock price following the release of disappointing Phase 3 trial results.
  • $55.75: The amount by which the stock price fell per share.
  • 10(b) and 20(a): The sections of the Securities Exchange Act of 1934 under which the lawsuit is filed.
  • 1:25-cv-08500: The case number of the lawsuit, Bridgewood v. MoonLake Immunotherapeutics, et al.

Sources:

  • GlobeNewswire (2025) - "Leading Securities Law Firm Announces Lawsuit Against MoonLake Immunotherapeutics and Certain of the Company's Senior Executives"
  • Bloomberg Law (2025) - "MoonLake Immunotherapeutics Stock Plunges After Clinical Trial Results Disappoint"
  • Lawdragon (2025) - "Bleichmar Fonti & Auld LLP Celebrates 10 Years of Success in Securities Class Actions"